Projectes per any
Resum
Cannabinoid receptor 1 (CB1) mediates the functional responses of Δ9-tetrahydrocannabinol. Although progress has been made in understanding cannabinoid binding and receptor activation, detailed knowledge of the dynamics involved in the activation mechanism of CB1 is lacking. Here, we use recently determined CB1 crystal structures to analyze its transition from inactive to active state by performing unbiased microsecond-length molecular dynamics (MD) simulations, totaling 32 μs, with and without bound potent cannabinoid agonist CP-55940. CB1 activation is characterized by an upward axial movement of transmembrane (TM) helix 3, inward movement of TM7, and outward movement of TM6. These conformational changes collectively allow Gi protein docking, although fully active states of the receptor occur only transiently during MD simulations. Additionally, positive allosteric modulation of CB1 by anionic phospholipids is found to increase action of the bound agonist. Specifically, this involves protein-lipid interactions at intracellular loop 3, TM6, and ionic lock residue Arg2143.50.
Idioma original | Anglès |
---|---|
Pàgines (de-a) | 5638-5654 |
Nombre de pàgines | 17 |
Revista | Journal of Medicinal Chemistry |
Volum | 62 |
Número | 11 |
DOIs | |
Estat de la publicació | Publicada - 13 de juny 2019 |
Fingerprint
Navegar pels temes de recerca de 'Revealing the Mechanism of Agonist-Mediated Cannabinoid Receptor 1 (CB1) Activation and Phospholipid-Mediated Allosteric Modulation'. Junts formen un fingerprint únic.Projectes
- 2 Acabat
-
Aproximación multidisciplinar a la complejidad farmacológica de las dianas de fármacos para trastornos neurológicos y psiquiátricos
Giraldo Arjonilla, J. (PI), Ortiz de Pablo, J. (Co-Investigador/a Principal), Gil Giro, C. (Investigador/a) & Sabrià Pau, J. (Investigador/a)
Ministerio de Economía y Competitividad (MINECO)
1/01/18 → 30/06/21
Projecte: Projectes i Ajuts a la Recerca
-
Investigación mediante métodos matemáticos,computacionales y bioquímicos del crosstalk entre los receptores mGlu5 y D2:relevancia para el tratamiento de la esquizofrenia.
Ortiz de Pablo, J. (PI), Giraldo Arjonilla, J. (Co-Investigador/a Principal), ABASS, D. (Col.laborador/a), Cruz Barbosa, R. (Col.laborador/a), Gil Giro, C. (Investigador/a) & Sabrià Pau, J. (Investigador/a)
1/01/15 → 31/12/17
Projecte: Projectes i Ajuts a la Recerca